What Is GHK-Cu?

GHK-Cu is a naturally occurring copper-binding tripeptide, sequence Glycine-Histidine-Lysine bound to a copper (Cu²⁺) ion, first isolated from human albumin by Loren Pickart in the early 1970s. It is found in human plasma, saliva, and urine, and its concentration in plasma falls significantly with age: roughly 200 ng/mL in young adults, declining to under 100 ng/mL by the sixth decade. That decline paralleled Pickart's hypothesis that GHK-Cu plays a role in tissue maintenance and repair throughout life.

Unlike most peptides on this site, GHK-Cu is not synthetic in origin — it is a naturally occurring fragment that the body produces. The research program behind it is also older and more developed than for most compounds here, going back decades. That said, the research is concentrated primarily in Pickart's own group and in cosmetic/topical applications. The evidence for injectable or systemic use, which is what most biohacking community users pursue, is substantially thinner.

What Does the Research Say?

Evidence level: Preliminary — GHK-Cu has real topical human trial data for skin aging and wound healing, which is stronger than the evidence base for most compounds in this space. Systemic injectable evidence is mostly animal and cell culture. The gene regulation claims from Pickart's later work are scientifically interesting but not validated by clinical outcome trials.

Mechanism

GHK-Cu has several documented mechanisms of action. The most established are promotion of collagen synthesis and wound healing, mediated through TGF-beta and PDGF growth factor signaling, and through modulation of matrix metalloproteinases (MMPs) that regulate extracellular matrix remodeling. The copper component contributes directly: copper is a cofactor for lysyl oxidase, an enzyme that crosslinks collagen and elastin, and many of GHK-Cu's tissue repair effects depend on delivering copper to relevant enzymes.

Anti-inflammatory activity via suppression of NF-κB signaling has been documented. VEGF (vascular endothelial growth factor) regulation is also reported, connecting to wound healing via angiogenesis.

Pickart's 2012 gene analysis work is the most frequently cited but also the most speculative piece of the mechanistic picture. Using bioinformatic analysis of published gene expression data, his group identified GHK as associated with upregulation of genes involved in antioxidant defense, DNA repair, and anti-inflammatory pathways, and downregulation of genes involved in cancer and inflammation. This is a hypothesis-generating analysis, not a controlled experiment, and its clinical implications are unclear. It gets circulated in longevity communities well beyond what the data supports.

Animal Studies

Animal studies on GHK-Cu cover wound healing, hair follicle stimulation, and bone density. Wound healing studies in rodents consistently show faster closure and better tissue quality with GHK-Cu treatment, consistent with the collagen and growth factor mechanisms. Hair follicle studies in mice showed increased follicle size and hair growth with topical application, which drove subsequent interest in hair loss applications. Bone density improvements in animal models have also been published.

These findings are internally consistent and align with the mechanism. They have not been extensively replicated by groups outside Pickart's research circle.

Human Studies

GHK-Cu is the only compound on this site with published human randomized controlled trial data for a topical application. Several studies examining topical GHK-Cu creams for facial skin aging have shown statistically significant improvements in skin density, thickness, fine lines, and laxity compared to controls. These trials are small (typically 20 to 40 participants) and often sponsored by cosmetic companies, but they exist — which is more than most peptides in this category can say.

The wound healing evidence in humans is also real, though less systematically organized. GHK-Cu has been used as a component of wound care preparations, and clinical observations in that context have been positive.

For injectable or systemic GHK-Cu — the form used in biohacking contexts — there are no published human RCTs. The evidence for systemic use rests on the topical and animal data, with the assumption that similar tissue repair and anti-aging mechanisms would operate systemically. That assumption is biologically plausible but not tested.

Community and Anecdotal Reports

GHK-Cu occupies an unusual position in peptide communities. Some users take it systemically (injected), reasoning from the topical evidence and the gene regulation claims. Others use it topically as part of a skincare routine, often in commercially available serums that list GHK-Cu as an ingredient. The two applications use very different formulations, concentrations, and routes.

Users of injected GHK-Cu report improved wound healing, skin quality, and sometimes hair density changes. The reports are consistent with the mechanism and the topical human data, but they come from uncontrolled self-experimentation where attribution is difficult. Users who take it topically often report visible skin improvements, which aligns more directly with the RCT evidence.

Common Uses

Skin Aging and Anti-Aging Skincare

This is the most evidence-backed application. Topical GHK-Cu has human RCT data showing improvements in skin aging markers. It is a common ingredient in high-end skincare serums and wound care preparations. The evidence for this application is stronger than for most other uses.

Wound Healing

One of the oldest documented applications. The collagen synthesis and growth factor mechanisms translate directly to wound repair. The topical wound care evidence is real; injectable wound healing in humans has not been formally studied.

Hair Growth

Animal studies and community reports support hair follicle stimulation. Some small human topical studies for hair growth exist but are limited in scope. GHK-Cu is found in some hair care formulations on this basis.

Systemic Anti-Aging

The injectable systemic use case rests on extrapolating from topical evidence and the gene regulation work. The mechanism is biologically coherent. Clinical evidence for systemic use in humans does not exist.

Delivery Methods

Topical

Topical application is the best-supported delivery method. GHK-Cu is used in serums and creams at concentrations typically ranging from 0.1% to 3%. This is the form with human RCT evidence. Commercially available cosmetic products containing GHK-Cu exist and are accessible without a prescription or research chemical sourcing.

Subcutaneous Injection

Injectable GHK-Cu is used in biohacking and peptide communities, reconstituted from lyophilized powder and injected subcutaneously. This route is intended to deliver GHK-Cu systemically for tissue repair and anti-aging effects. No pharmacokinetic data specifically comparing injectable to topical GHK-Cu in humans has been published.

PEPVi does not provide dosing guidance. Dosing decisions should be made in consultation with a qualified healthcare provider.

Safety and Side Effects

GHK-Cu has a well-established safety profile for topical use, supported by decades of cosmetic application. Skin irritation with higher concentrations is the main topical concern. Systemic or injectable use has no comparable safety data.

Copper is an essential micronutrient, but copper toxicity at excessive levels is a real concern. The doses of copper delivered by GHK-Cu use at typical concentrations are generally considered small relative to daily dietary copper intake, but this has not been formally evaluated for injectable use at frequency. People with Wilson's disease (a genetic disorder of copper metabolism) should not use GHK-Cu.

No serious adverse events have been documented in the topical human studies. Long-term safety data for systemic injectable use does not exist.

GHK-Cu is not FDA-approved for any indication as an injectable compound. In topical cosmetic formulations it is sold without restriction and does not require a prescription. It is not a scheduled controlled substance.

As an injectable compound, GHK-Cu occupies the same research-compound status as other peptides on this site. Access through compounding pharmacies has been affected by the FDA's broader compounding restrictions, though GHK-Cu's regulatory status has not been as specifically debated as some other peptides.

GHK-Cu is one of the 12 peptides targeted in the current reclassification process. For details on what changes in July 2026, see What RFK's Peptide Reclassification Means for You.

Frequently Asked Questions

It's naturally occurring (not synthetic), has a much longer research history, and has actual human topical trial data for skin aging. Most peptides in this space have animal data and Russian clinical trials; GHK-Cu has Western cosmetic dermatology studies. The injectable systemic application is less studied than for some other compounds here.

The RCT data says yes for the specific endpoints studied (skin density, fine lines, laxity). The trials are small and often industry-funded, but they are randomized controlled trials in humans — a higher bar than most compounds in this space clear. The effect sizes are meaningful if not dramatic.

Unknown. The topical application has human evidence; injectable use doesn't. Whether systemic GHK-Cu produces the same tissue effects as topical application, or different effects through different mechanisms, has not been studied. The assumption that injectable is more effective or more broadly active is plausible but untested.

Topical use has a decades-long safety record and is well-established. Injectable use lacks equivalent safety data. The copper component is the main specific concern for systemic use — copper toxicity is a real phenomenon, and the systemic copper exposure from injectable GHK-Cu at various doses has not been characterized. People with Wilson's disease should not use it.

Learn More

Sources

  1. Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." International Journal of Molecular Sciences, 2018. — Review of GHK-Cu's gene regulatory effects using bioinformatic analysis; the primary source for the antioxidant and anti-aging gene regulation claims.

  2. Pickart L. "The human tri-peptide GHK and tissue remodeling." Journal of Biomaterials Science, Polymer Edition, 2008. — Overview of GHK's mechanisms in wound healing, collagen synthesis, and tissue repair; covers the growth factor and MMP mechanisms underlying the wound healing application.

  3. Abdulghani AA, Sherr S, Shirin S, et al. "Effects of topical creams containing vitamin C, a copper-binding peptide cream and melatonin compared with tretinoin on the ultrastructure of normal skin — a pilot clinical, histologic, and ultrastructural study." Disease Management and Clinical Outcomes, 1998. — Early comparative trial examining topical copper peptide effects on skin ultrastructure; part of the human topical evidence base for skin aging applications.